RECRUITINGPhase 2INTERVENTIONAL
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
About This Trial
To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.
Who May Be Eligible (Plain English)
Who May Qualify:
- Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines
Who Should NOT Join This Trial:
- Pregnant or nursing patients
- Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
- Patients with an active lung neoplasm or any active neoplasm for blood samples
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines
Exclusion Criteria:
* Pregnant or nursing patients
* Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study.
* Patients with an active lung neoplasm or any active neoplasm for blood samples
Treatments Being Tested
DIAGNOSTIC_TEST
FAPI PET/CT
In the department of Nuclear Medicine: * Installation in a relax chair after weight and height control * Placement of a venous line in the upper limb after which an infusion of 500ml of 0.9% NaCl is started. * Intravenous injection of 3 MBq/kg (max 300 MBq) of 18F- FAPI 74 or of 2 MBq/kg 68Ga-FAPI46
Locations (1)
Medecine
Brussels, Belgium